Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Tipo de estudo
Intervalo de ano de publicação
1.
Eur J Paediatr Neurol ; 28: 81-88, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-32811771

RESUMO

BACKGROUND: Neurodegeneration with brain iron accumulation constitutes a group of rare progressive movement disorders sharing intellectual disability and neuroimaging findings as common denominators. Beta-propeller protein-associated neurodegeneration (BPAN) represents approximately 7% of the cases, and its first signs are typically epilepsy and developmental delay. We aimed to describe in detail the phenotype of BPAN with a special focus on iron metabolism. MATERIAL AND METHODS: We present a cohort of paediatric patients with pathogenic variants of WD-Repeat Domain 45 gene (WDR45). The diagnosis was established by targeted panel sequencing of genes associated with epileptic encephalopathies (n = 9) or by Sanger sequencing of WDR45 (n = 1). Data on clinical characteristics, molecular-genetic findings and other performed investigations were gathered from all participating centres. Markers of iron metabolism were analysed in 6 patients. RESULTS: Ten children (3 males, 7 females, median age 8.4 years) from five centres (Prague, Berlin, Vogtareuth, Tubingen and Cologne) were enrolled in the study. All patients manifested first symptoms (e.g. epilepsy, developmental delay) between 2 and 31 months (median 16 months). Seven patients were seizure-free (6 on antiepileptic medication, one drug-free) at the time of data collection. Neurological findings were non-specific with deep tendon hyperreflexia (n = 4) and orofacial dystonia (n = 3) being the most common. Soluble transferrin receptor/log ferritin ratio was elevated in 5/6 examined subjects; other parameters of iron metabolism were normal. CONCLUSION: Severity of epilepsy often gradually decreases in BPAN patients. Elevation of soluble transferrin receptor/log ferritin ratio could be another biochemical marker of the disease and should be explored by further studies.


Assuntos
Proteínas de Transporte/genética , Distúrbios do Metabolismo do Ferro/genética , Distúrbios do Metabolismo do Ferro/metabolismo , Ferro/sangue , Doenças Neurodegenerativas/genética , Doenças Neurodegenerativas/metabolismo , Biomarcadores/sangue , Criança , Epilepsia/sangue , Epilepsia/genética , Epilepsia/metabolismo , Feminino , Humanos , Deficiência Intelectual/sangue , Deficiência Intelectual/genética , Deficiência Intelectual/metabolismo , Distúrbios do Metabolismo do Ferro/sangue , Masculino , Transtornos dos Movimentos/sangue , Transtornos dos Movimentos/genética , Transtornos dos Movimentos/metabolismo , Doenças Neurodegenerativas/sangue , Fenótipo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA